These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 19904272)

  • 21. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC).
    Roobol MJ; Kerkhof M; Schröder FH; Cuzick J; Sasieni P; Hakama M; Stenman UH; Ciatto S; Nelen V; Kwiatkowski M; Lujan M; Lilja H; Zappa M; Denis L; Recker F; Berenguer A; Ruutu M; Kujala P; Bangma CH; Aus G; Tammela TL; Villers A; Rebillard X; Moss SM; de Koning HJ; Hugosson J; Auvinen A
    Eur Urol; 2009 Oct; 56(4):584-91. PubMed ID: 19660851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
    Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
    Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [PSA screening and molecular markers].
    Lakes J; Arsov C
    Urologe A; 2019 May; 58(5):486-493. PubMed ID: 30874831
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overdetection in screening for prostate cancer.
    Hugosson J; Carlsson S
    Curr Opin Urol; 2014 May; 24(3):256-63. PubMed ID: 24670870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current and projected annual direct costs of screening asymptomatic men for prostate cancer using prostate-specific antigen.
    Krahn MD; Coombs A; Levy IG
    CMAJ; 1999 Jan; 160(1):49-57. PubMed ID: 9934343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The socioeconomic implications of prostate-specific antigen screening.
    Benoit RM; Naslund MJ
    Urol Clin North Am; 1997 May; 24(2):451-8. PubMed ID: 9126243
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Cost-Utility Analysis of Prostate Cancer Screening in Australia.
    Keller A; Gericke C; Whitty JA; Yaxley J; Kua B; Coughlin G; Gianduzzo T
    Appl Health Econ Health Policy; 2017 Feb; 15(1):95-111. PubMed ID: 27757918
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer.
    Carter HB; Epstein JI; Chan DW; Fozard JL; Pearson JD
    JAMA; 1997 May; 277(18):1456-60. PubMed ID: 9145718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
    Roobol MJ; Roobol DW; Schröder FH
    Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence.
    Hayes JH; Barry MJ
    JAMA; 2014 Mar; 311(11):1143-9. PubMed ID: 24643604
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial.
    de Koning HJ; Auvinen A; Berenguer Sanchez A; Calais da Silva F; Ciatto S; Denis L; Gohagan JK; Hakama M; Hugosson J; Kranse R; Nelen V; Prorok PC; Schröder FH; ;
    Int J Cancer; 2002 Jan; 97(2):237-44. PubMed ID: 11774270
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Follow-up of men with elevated prostate-specific antigen and one set of benign biopsies at prostate cancer screening.
    Zackrisson B; Aus G; Lilja H; Lodding P; Pihl CG; Hugosson J
    Eur Urol; 2003 Apr; 43(4):327-32. PubMed ID: 12667711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Contamination in control group led to no effect of PSA-based screening on prostate cancer mortality at 9 years follow-up: Results of the French section of European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Villers A; Bessaoud F; Trétarre B; Grosclaude P; Malavaud B; Rebillard X; Iborra F; Daubisse L; Malavaud S; Roobol M; Heijnsdijk EA; de Koning HJ; Hugosson J; Rischmann P; Soulié M
    Prog Urol; 2020 Apr; 30(5):252-260. PubMed ID: 32197936
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-benefit analysis of total, free/total, and complexed prostate-specific antigen for prostate cancer screening.
    Ellison L; Cheli CD; Bright S; Veltri RW; Partin AW
    Urology; 2002 Oct; 60(4 Suppl 1):42-6. PubMed ID: 12384162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The value of different screening tests in predicting prostate biopsy outcome in screening for prostate cancer data from a multicenter study (ERSPC).
    Roobol MJ; Zappa M; Määttänen L; Ciatto S
    Prostate; 2007 Mar; 67(4):439-46. PubMed ID: 17192912
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Schröder FH
    Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of harms, benefits, and cost-effectiveness of prostate cancer screening: A micro-simulation study of 230 scenarios.
    Getaneh AM; Heijnsdijk EAM; Roobol MJ; de Koning HJ
    Cancer Med; 2020 Oct; 9(20):7742-7750. PubMed ID: 32813910
    [TBL] [Abstract][Full Text] [Related]  

  • 38. No reason for immediate repeat sextant biopsy after negative initial sextant biopsy in men with PSA level of 4.0 ng/mL or greater (ERSPC, Rotterdam).
    Roobol MJ; van der Cruijsen IW; Schröder FH
    Urology; 2004 May; 63(5):892-7; discussion 897-9. PubMed ID: 15134973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population screening for prostate cancer and emerging concepts for young men.
    Moul JW
    Clin Prostate Cancer; 2003 Sep; 2(2):87-97. PubMed ID: 15040869
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate-specific antigen: does the current evidence support its use in prostate cancer screening?
    Duffy MJ
    Ann Clin Biochem; 2011 Jul; 48(Pt 4):310-6. PubMed ID: 21525152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.